Replies to post #282265 on NorthWest Biotherapeutics Inc (NWBO)

[CogDiss 1188X]

Unless nwbo's tech has value, an acquirer would not be able to use most of the tax loss carryforward.

This is an interesting angle. Just how would a company demonstrate that NWBO’s technology has value, let’s say in an ambiguous TLD result that, theoretically, a deep-pocketed investor might want to pursue through a better designed trial? This seems like a case in which the technology has unrealized value.

Would it be possible to pursue and demonstrate that technology value in such a way as not to run afoul of the IRS and yet milk the tax loss carryforward in a way that they come out significantly ahead?

[Doc logic]

JerryCampbell,

I defiantly missed your point as I was only responding to your one post I saw on this thread. I was also looking at this as a minor point since my position is based on a platform technology being validated at some point and expanded rapidly into multiple indications because of safety and ability to potentiate other treatments. There is no way all regulators will look past these points and the fact that at least a subgroup is responding incredibly well while others receive modest improvements. Best wishes.